PLEASANTON, Calif., May 11, 2017 -- Natus Medical Incorporated (NASDAQ:BABY) today announced that the Company will host an analyst day in New York, New York on Thursday, June 22, 2017. The meeting will be held at the Sofitel New York Hotel.
Members of Natus Medical’s management team will host a series of presentations beginning at 9:00 a.m. Eastern Time. A live webcast of the event will be available at http://investor.natus.com and an archive will also be available. Space for the event is limited and pre-registration is required. For additional information on the event, please contact Natus investor relations at [email protected].
About Natus Medical Incorporated
Natus is a leading provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Additional information about Natus Medical can be found at www.natus.com.
COMPANY CONTACT: Natus Medical Incorporated Jonathan A. Kennedy Executive Vice President and Chief Financial Officer (925) 223-6700 [email protected]


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Washington Post Publisher Will Lewis Steps Down After Layoffs 



